Navigation Links
Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics
Date:12/20/2011

CAMBRIDGE, England, December 21, 2011 /PRNewswire/ --

Arecor Limited has entered into a collaboration agreement with Eli Lilly and Company to assess Arecor's advanced protein formulation technologies for possible use with Lilly's growing pipeline of biological-based drugs.  Under this agreement, Arecor will develop stable aqueous or higher concentration formulations of emerging protein and peptide drug candidates developed by Lilly.  In addition, Arecor will work with Lilly to potentially offer improved formulations of Lilly's existing therapeutic proteins in several therapeutic areas.  

Tom Saylor, CEO of Arecor, stated, "The next generation of protein and peptide therapeutics present significant formulation challenges. Arecor's stabilization tools may enable new products and presentations, which would otherwise not be possible, without additional processing or changes to standard manufacturing practices.  Lilly's strong support of innovation and emerging technologies offers Arecor the potential to apply Arecor's broad-ranging expertise in biomolecule stabilization to a leader in pharmaceutical application of the next generation of biologics."

Arecor is a pioneer in the stabilization of biologic molecules, a key challenge in the development of many therapeutic proteins, vaccines and diagnostics. Arecor Limited was established to provide formulation solutions to pharmaceutical and biotech companies developing proteins, vaccines and diagnostics based upon new insights into interactions between proteins and their immediate environment. Proteins and vaccines are often fragile entities, and stability can represent significant constraints in the development of new products and extending the use of existing products. Arecor has developed Arestat™, a patented set of tools for stabilization which address the main pathways of degradation. As a simple reformulation, Arestat™ can be readily incorporated into standard manufacturing practice, without covalent modification of the biologic and using excipients approved for the route of delivery. Arecor currently has active feasibility programs and licenses with many of the top pharmaceutical and biotech companies on a wide range of proteins and vaccines.

Contact:

Tom Saylor, CEO
tsaylor@arecor.com
Arecor Limited
2 Cambridge Science Park
Cambridge, UK
http://www.arecor.com


'/>"/>
SOURCE Arecor
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuse Science Announces the Launch of its Analgesic and Diabetic Oral Fuse Delivery (OFD) Research Project Platforms
2. Enlight Biosciences Forms New Partnerships with AstraZeneca and Novo Nordisk
3. Diablo Valley Oncology Performs Breast Intraoperative Radiation Procedure - First in the East Bay
4. Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
5. ArjoHuntleigh Forms New Division to Enhance the Quality Home Medical Care
6. Digital ArtForms Debuts iMedic3D, a Radically Different Approach to Radiology, at RSNA ‘11, and Announces the Addition of Dr. Eliot Siegel and Dr. David Kim to Its Advisory Board Members
7. Awarepoint Corporation and MEDITECH Collaborate to Integrate Technology Platforms
8. Mindray Introduces Enhancements for M Series Ultrasound Platforms at ASA
9. ContinuumRx Forms Healthcare Joint Venture with Mississippi Baptist Health Systems
10. Stereotaxis Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms
11. Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  The National Pharmaceutical ... joined the health policy research organization as its ... , MD, senior vice president and chief scientific ... representative on the NPC Board of Directors. ... that Mallinckrodt has joined us in support of ...
(Date:6/23/2016)... 23, 2016  Delcath Systems, Inc. (NASDAQ: ... focused on treatment of primary and metastatic liver cancers, ... education - www.againsttheodds.eu - has been awarded ... Awards. The website was developed ... and their families who are coping with the devastating ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. Stock-Callers.com has initiated coverage on the following equities: ... (NASDAQ: AMAG ), IDEXX Laboratories Inc. (NASDAQ: ... ADRO ). Learn more about these stocks by accessing their ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... and infrastructure. Most providers, however, are unsure how to move forward, given the ... to define a path forward tailored to an organization’s specific needs. , PYA ...
Breaking Medicine News(10 mins):